MX2020003504A - Receptores de celulas t que reconocen p53 mutado. - Google Patents

Receptores de celulas t que reconocen p53 mutado.

Info

Publication number
MX2020003504A
MX2020003504A MX2020003504A MX2020003504A MX2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A
Authority
MX
Mexico
Prior art keywords
cell receptors
mammal
methods
recognize mutated
cancer
Prior art date
Application number
MX2020003504A
Other languages
English (en)
Other versions
MX421596B (es
Inventor
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Drew C Deniger
Anna Pasetto
Winifred M Lo
Yong-Chen Lu
Maria R Parkhurst
Parisa Malekzadeh
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2020003504A publication Critical patent/MX2020003504A/es
Publication of MX421596B publication Critical patent/MX421596B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un receptor de células T (TCR) aislado o purificado que tiene especificidad antigénica para p53 humano mutado. También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos, vectores de expresión recombinante, células hospedadoras, poblaciones de células y composiciones farmacéuticas relacionadas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir cáncer en un mamífero.
MX2020003504A 2017-09-29 2018-09-17 Receptores de celulas t que reconocen p53 mutado MX421596B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (2)

Publication Number Publication Date
MX2020003504A true MX2020003504A (es) 2020-09-14
MX421596B MX421596B (es) 2025-03-14

Family

ID=63714167

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2020003504A MX421596B (es) 2017-09-29 2018-09-17 Receptores de celulas t que reconocen p53 mutado
MX2024005677A MX2024005677A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.
MX2024005676A MX2024005676A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.
MX2024005678A MX2024005678A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2024005677A MX2024005677A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.
MX2024005676A MX2024005676A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.
MX2024005678A MX2024005678A (es) 2017-09-29 2020-07-13 Receptores de celulas t que reconocen p53 mutado.

Country Status (20)

Country Link
US (2) US11939365B2 (es)
EP (2) EP4647442A3 (es)
JP (3) JP7324193B2 (es)
KR (2) KR20250024096A (es)
CN (2) CN118955684A (es)
AU (2) AU2018342246B2 (es)
BR (1) BR112020006012A2 (es)
CA (1) CA3077024A1 (es)
CR (4) CR20200170A (es)
DK (1) DK3688027T3 (es)
EA (1) EA202090757A1 (es)
ES (1) ES3056082T3 (es)
FI (1) FI3688027T3 (es)
IL (1) IL273515B2 (es)
MA (1) MA50651A (es)
MX (4) MX421596B (es)
PL (1) PL3688027T3 (es)
PT (1) PT3688027T (es)
SG (1) SG11202002636PA (es)
WO (1) WO2019067243A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
SG11202002635RA (en) * 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
TW202525841A (zh) * 2019-06-27 2025-07-01 美國衛生與公眾服務部 識別p53中之r175h或y220c突變之t細胞受體
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
TWI900647B (zh) * 2020-09-04 2025-10-11 美國衛生與公眾服務部 識別p53中r273c或y220c突變的t細胞受體
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
JP2024517884A (ja) * 2021-05-07 2024-04-23 アメリカ合衆国 ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
JP2024540197A (ja) * 2021-10-29 2024-10-31 ホウ，ヤフェイ Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2025024648A2 (en) * 2023-07-25 2025-01-30 Memorial Sloan-Kettering Cancer Center T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
WO2025226769A1 (en) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. T cell receptors targeting minor histocompatibility antigen lrh-1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
CA2487779C (en) * 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
HUE049292T2 (hu) * 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
KR102375998B1 (ko) * 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
MX375379B (es) 2014-05-29 2025-03-06 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
EP3265079A4 (en) 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
WO2016179006A1 (en) * 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use

Also Published As

Publication number Publication date
MX421596B (es) 2025-03-14
IL273515B2 (en) 2026-03-01
PL3688027T3 (pl) 2026-04-07
AU2018342246A1 (en) 2020-04-16
EP3688027B1 (en) 2025-09-10
KR20250024096A (ko) 2025-02-18
EP4647442A3 (en) 2026-03-04
MX2024005676A (es) 2024-06-11
CN118955684A (zh) 2024-11-15
CN111386282B (zh) 2024-09-06
IL273515A (en) 2020-05-31
ES3056082T3 (en) 2026-02-18
AU2024227695A1 (en) 2024-12-05
US11939365B2 (en) 2024-03-26
BR112020006012A2 (pt) 2020-10-06
IL273515B1 (en) 2025-11-01
MA50651A (fr) 2020-08-05
AU2018342246B2 (en) 2024-08-08
KR102762272B1 (ko) 2025-02-07
CR20240303A (es) 2024-09-04
JP2025020145A (ja) 2025-02-12
JP2023159112A (ja) 2023-10-31
KR20200064110A (ko) 2020-06-05
CR20200170A (es) 2020-11-23
PT3688027T (pt) 2025-12-16
JP7573075B2 (ja) 2024-10-24
FI3688027T3 (fi) 2025-12-09
JP2021500010A (ja) 2021-01-07
SG11202002636PA (en) 2020-04-29
WO2019067243A1 (en) 2019-04-04
CN111386282A (zh) 2020-07-07
JP7324193B2 (ja) 2023-08-09
CR20240302A (es) 2024-11-07
US20200277352A1 (en) 2020-09-03
JP7814467B2 (ja) 2026-02-16
CR20250153A (es) 2025-06-03
CA3077024A1 (en) 2019-04-04
MX2024005677A (es) 2024-06-11
EP3688027A1 (en) 2020-08-05
EP4647442A2 (en) 2025-11-12
MX2024005678A (es) 2024-06-11
EA202090757A1 (ru) 2020-08-21
DK3688027T3 (da) 2025-12-15
US20240270814A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
MX2020009472A (es) Receptores de antigenos quimericos anti-cd33 y sus usos.
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX384212B (es) Metodos para cosechar cultivos de celulas de mamifero.
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
BR112019004017A2 (pt) proteínas quiméricas para direcionar dsrna